Opsumit

Active Ingredient(s): Macitentan
FDA Approved: * October 18, 2013
Pharm Company: * ACTELION PHARMS LTD
Category: Blood Pressure

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Opsumit Overview

Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).[1] The other two ERAs marketed as of 2014 are bosentan and ambrisentan.[1] Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB.[1] However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.&...

Read more Opsumit Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Macitentan

Recent Opsumit Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Opsumit: (1 result)

Sorted by National Drug Code

• 66215-501 Opsumit (Macitentan 10 mg) by Actelion Pharmaceuticals Us, Inc.

Other drugs which contain Macitentan or a similar ingredient: (1 result)

• MACITENTAN